Washington Medicaid and tirzepatide
Zepbound for weight loss: no. Not covered for weight loss. The policy has an approval path for moderate to severe sleep apnea in adults with BMI above 30, with prior authorization. Age 20 and younger follow EPSDT rules. Mounjaro for weight loss: no. State rule excludes any drug prescribed for weight loss. The GLP-1 policy requires a type 2 diabetes diagnosis or qualifying HbA1c, including its sleep apnea path, with prior authorization.; for type 2 diabetes Washington Medicaid must cover it. Read from Washington State Health Care Authority documents Nov 6, 2026.
Zepbound · Washington State Health Care Authority
“Tirzepatide (Zepbound®) is not covered by Apple Health for weight loss in accordance with:”
read Nov 6, 2026
Mounjaro · Washington State Health Care Authority
“Tirzepatide (Mounjaro) may be approved when all of the following documented criteria are met: 1. Diagnosis of Type 2 diabetes or an HbA1c ≥ 6.5 within the last 12 months;”
read Nov 6, 2026
In 2025 Washington Medicaid paid for 23,929 tirzepatide prescriptions (Mounjaro, Zepbound), 22% of its GLP-1 prescriptions and 21st of the 50 states and DC. It reimbursed $24.0 million before rebates, $1,004 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 21,682 | $21.7 million | $999 |
| Zepbound | 2,247 | $2.4 million | $1,060 |
Washington plans and prescribing rules
Washington Public Employees Benefits Board (PEBB) program. No Washington PEBB plan covers GLP-1 drugs for weight loss, as of the Health Care Authority's February 2026 newsletter.
Premera Blue Cross. Premera Blue Cross covers weight-management GLP-1s only when an employer group elects that benefit. In 2026 it added GLP-1 Access Select, an employer option that sets a BMI threshold of 35 for weight-loss GLP-1s.



